Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 8/20 | 0.43 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490673 | 0.91 | ANO1 (0.45) | ANO1ANO2DHODHMEN1NPC1 | |
| SCHEMBL1490517 | 0.88 | ANO1 (0.47) | ANO1ANO2NPC1RAB9AKMT2A | |
| SCHEMBL12756913 | 0.87 | RAB9A (0.45) | ANO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL12830929 | 0.86 | ANO1 (0.43) | ANO1SIRT5KCNMA1 | |
| SCHEMBL12756911 | 0.85 | MEN1 (0.37) | ANO1SIRT5MEN1NPC1RAB9A | |
| SCHEMBL1490568 | 0.83 | MEN1 (0.49) | MEN1NPC1RAB9AKMT2ACASP3 | |
| SCHEMBL1490587 | 0.83 | ANO1 (0.44) | ANO1ANO2DHODHMEN1NPC1 | |
| SCHEMBL1490367 | 0.81 | MEN1 (0.50) | MEN1NPC1RAB9AKMT2ACASP3 | |
| SCHEMBL1490642 | 0.81 | KMT2A (0.53) | ANO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL12756912 | 0.81 | NPC1 (0.39) | ANO1DHODHMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885ANO2 98/4885SIRT5 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.